| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
32 |
S7 |
p. viii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
32 |
S7 |
p. i
|
artikel
|
| 3 |
ESMO
|
|
|
|
32 |
S7 |
p. v-vi
|
artikel
|
| 4 |
Journal Information
|
|
|
|
32 |
S7 |
p. ii
|
artikel
|
| 5 |
LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors
|
Haanen, J.
|
|
|
32 |
S7 |
p. S1392
|
artikel
|
| 6 |
LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial
|
Shang, X.
|
|
|
32 |
S7 |
p. S1428-S1429
|
artikel
|
| 7 |
LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial
|
Han, B.
|
|
|
32 |
S7 |
p. S1429
|
artikel
|
| 8 |
LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
|
Cho, B.C.
|
|
|
32 |
S7 |
p. S1428
|
artikel
|
| 9 |
47MO Metabolic intervention during CAR T-cell manufacturing improves persistence and antitumor efficacy
|
Wenes, M.
|
|
|
32 |
S7 |
p. S1393
|
artikel
|
| 10 |
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
|
Colevas, D.A.
|
|
|
32 |
S7 |
p. S1432
|
artikel
|
| 11 |
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
|
Reck, M.
|
|
|
32 |
S7 |
p. S1430-S1431
|
artikel
|
| 12 |
46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
|
Adusumilli, P.S.
|
|
|
32 |
S7 |
p. S1392-S1393
|
artikel
|
| 13 |
48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors
|
Park, J-C.
|
|
|
32 |
S7 |
p. S1393
|
artikel
|
| 14 |
Notice and Disclaimer
|
|
|
|
32 |
S7 |
p. iii
|
artikel
|
| 15 |
1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
|
Kris, M.G.
|
|
|
32 |
S7 |
p. S1373
|
artikel
|
| 16 |
3O Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of three clinical trials
|
Zhou, J-G.
|
|
|
32 |
S7 |
p. S1375
|
artikel
|
| 17 |
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
|
Zhou, C.
|
|
|
32 |
S7 |
p. S1374
|
artikel
|
| 18 |
4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
|
Ramalingam, S.S.
|
|
|
32 |
S7 |
p. S1375-S1376
|
artikel
|
| 19 |
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
|
Yang, J.C-H.
|
|
|
32 |
S7 |
p. S1429-S1430
|
artikel
|
| 20 |
121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
|
Yang, Y.
|
|
|
32 |
S7 |
p. S1430
|
artikel
|
| 21 |
23P A comprehensive analysis of the mucosal melanoma immune microenvironment
|
Vos, J.
|
|
|
32 |
S7 |
p. S1383
|
artikel
|
| 22 |
86P Adjusting ORIENT-11 trial (O-11) results to a US patient population
|
Nagasaka, M.
|
|
|
32 |
S7 |
p. S1409-S1410
|
artikel
|
| 23 |
54P AKT inhibition during ex vivo tumor-infiltrating lymphocyte (TIL) expansion enhances cytokine production and function while increasing the population of less differentiated (CD39-CD69-) CD8+ T-cells
|
Cubas, R.
|
|
|
32 |
S7 |
p. S1395
|
artikel
|
| 24 |
36P Alterations in tumour-promoting cytokines in cancer patients after SARS-CoV-2 infection
|
De Winter, F.H.
|
|
|
32 |
S7 |
p. S1387-S1388
|
artikel
|
| 25 |
53P A multispecific non-integrating RNA CAR T platform to overcome the clinical challenge of glioblastoma heterogeneity
|
Martínez Bedoya, D.
|
|
|
32 |
S7 |
p. S1395
|
artikel
|
| 26 |
45P A novel bi-functional IL15 cytokine fusion antibody selected to kill B7-H4 positive tumor cells
|
Chang, T-P.
|
|
|
32 |
S7 |
p. S1391
|
artikel
|
| 27 |
183P A novel human immunocompetent platform for immunotherapy screening
|
Marzagalli, M.
|
|
|
32 |
S7 |
p. S1461-S1462
|
artikel
|
| 28 |
171P An unwelcome guest: P. gingivalis intratumoral infection and immune evasion in gastric cancer
|
Retamal, I.N.
|
|
|
32 |
S7 |
p. S1458
|
artikel
|
| 29 |
68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
|
Kudo, M.
|
|
|
32 |
S7 |
p. S1401-S1402
|
artikel
|
| 30 |
49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results
|
Ridolfi, L.
|
|
|
32 |
S7 |
p. S1394
|
artikel
|
| 31 |
148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
|
Han, B.
|
|
|
32 |
S7 |
p. S1443-S1444
|
artikel
|
| 32 |
18P A radiomic approach to differentiate the immunotherapy-induced pneumonitis in patients with stage IV NSCLC
|
Romita, A.
|
|
|
32 |
S7 |
p. S1381
|
artikel
|
| 33 |
43P Assessment of biomarker kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab
|
Zhao, H.
|
|
|
32 |
S7 |
p. S1389-S1390
|
artikel
|
| 34 |
161P Assessment of corticosteroid premedication for patients treated with the humanized GD2-binding monoclonal antibody naxitamab
|
Mora, J.
|
|
|
32 |
S7 |
p. S1451
|
artikel
|
| 35 |
25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
|
Riudavets Melia, M.
|
|
|
32 |
S7 |
p. S1384
|
artikel
|
| 36 |
83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials
|
Nassif, E.
|
|
|
32 |
S7 |
p. S1407-S1408
|
artikel
|
| 37 |
184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer
|
Gorría Puga, T.
|
|
|
32 |
S7 |
p. S1462
|
artikel
|
| 38 |
44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors
|
Hecht, J.R.
|
|
|
32 |
S7 |
p. S1390-S1391
|
artikel
|
| 39 |
12P Blood-based biomarker analysis for predicting efficacy of definitive concurrent chemoradiotherapy and durvalumab consolidation in patients with unresectable locally advanced non-small cell lung cancer
|
Park, C-K.
|
|
|
32 |
S7 |
p. S1379
|
artikel
|
| 40 |
129P BYON4228 is a pan-allelic SIRPα antibody that potentiates killing of antibody-opsonized tumor cells and lacks binding to T-cells
|
Helden, M.V.
|
|
|
32 |
S7 |
p. S1433-S1434
|
artikel
|
| 41 |
42P CAMOIP: A web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
|
Luo, P.
|
|
|
32 |
S7 |
p. S1389
|
artikel
|
| 42 |
98P Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
|
Xu, C.
|
|
|
32 |
S7 |
p. S1417
|
artikel
|
| 43 |
65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
|
Ma, J.
|
|
|
32 |
S7 |
p. S1400
|
artikel
|
| 44 |
66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
|
Wang, X.
|
|
|
32 |
S7 |
p. S1400
|
artikel
|
| 45 |
39P Cancers with Ochrobactrum anthropi infection show enhanced responses to immune checkpoint blockade treatment
|
Wei, J.
|
|
|
32 |
S7 |
p. S1388-S1389
|
artikel
|
| 46 |
32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?
|
Brando, C.
|
|
|
32 |
S7 |
p. S1386
|
artikel
|
| 47 |
78P Cardiotoxicity in cancer patients treated with immune-checkpoint inhibitors
|
Franco, F.F.
|
|
|
32 |
S7 |
p. S1406
|
artikel
|
| 48 |
73P Characteristics and outcomes of emergency presentations due to immune-mediated toxicities
|
Nahm, S.
|
|
|
32 |
S7 |
p. S1403-S1404
|
artikel
|
| 49 |
14P Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of sintilimab plus docetaxel in previously treated advanced non-small cell lung cancer
|
Wang, Z.
|
|
|
32 |
S7 |
p. S1380
|
artikel
|
| 50 |
88P Clinical outcomes in patients with metastatic (m+) melanoma treated with immune-checkpoint inhibitors (ICI) with or without radiotherapy (RT): A monocentric retrospective study
|
Grimaudo, M.S.
|
|
|
32 |
S7 |
p. S1410
|
artikel
|
| 51 |
81P Clinical value of routine FDG-PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma
|
Ellebaek, E.
|
|
|
32 |
S7 |
p. S1407
|
artikel
|
| 52 |
28P Combination of tertiary lymphoid structure and neutrophil-to-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma
|
Wen, S.
|
|
|
32 |
S7 |
p. S1385
|
artikel
|
| 53 |
175P Combined efforts of LncRNAs DILC and atezolizumab to regulate MMP-9 release in tumor microenvironment of TNBC TAMs and cells lines
|
Samir, A.
|
|
|
32 |
S7 |
p. S1459
|
artikel
|
| 54 |
69P Combining sintilimab with anlotinib as second-line or later therapy in patients with extensive-disease small cell lung cancer: A prospective, single-arm, phase II trial
|
Shuxiang, M.
|
|
|
32 |
S7 |
p. S1402
|
artikel
|
| 55 |
5P Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)
|
König, D.
|
|
|
32 |
S7 |
p. S1376
|
artikel
|
| 56 |
182P Comprehensive assessment of the immunophenotype of peripheral blood lymphocytes, inflammatory factors, the immunophenotype of lymphocytes infiltrating the tumor and clinical indicators for overall survival and progression-free survival in patients with gastric cancer
|
Khakimova, G.
|
|
|
32 |
S7 |
p. S1461
|
artikel
|
| 57 |
22P Comprehensive statistical analysis of predictive markers to immune checkpoint inhibitors in patients with non-small cell lung cancer
|
Hiltbrunner, S.
|
|
|
32 |
S7 |
p. S1382
|
artikel
|
| 58 |
151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)
|
Xue, Q.
|
|
|
32 |
S7 |
p. S1445-S1446
|
artikel
|
| 59 |
60P CXCR2 antagonist revoked TGF-β elevation in chemo-resistant triple negative breast cancer cells
|
Ghallab, A.
|
|
|
32 |
S7 |
p. S1397
|
artikel
|
| 60 |
80P Defining the correlation between immune-checkpoint inhibitors-related adverse events and survival outcomes: A systematic review and meta-analysis
|
Abdihamid, O.
|
|
|
32 |
S7 |
p. S1406-S1407
|
artikel
|
| 61 |
186P Determination of the number of suppressor cells of myeloid origin in blood and tumor microcirculation in patients with locally advanced and metastatic lung cancer
|
Vukovic, J.
|
|
|
32 |
S7 |
p. S1463
|
artikel
|
| 62 |
30P Differential expression of miR-873, miR-181a and miR-17-5p and their correlation with immune checkpoints PD-L1 and CD155 among hepatocellular carcinoma patients
|
Eltahtawy, O.
|
|
|
32 |
S7 |
p. S1385-S1386
|
artikel
|
| 63 |
7P Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC
|
Rocha, P.
|
|
|
32 |
S7 |
p. S1377
|
artikel
|
| 64 |
57P 3D-printable plastics compatible with CAR T-cell production
|
Bire, S.
|
|
|
32 |
S7 |
p. S1396
|
artikel
|
| 65 |
134P Drugless nanoparticles tune-up immune components at triple negative breast cancer tumor microenvironment milieu
|
Ramzy, A.
|
|
|
32 |
S7 |
p. S1435
|
artikel
|
| 66 |
158P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic NSCLC (mNSCLC): Pharmacokinetics (PK) and anti-drug antibody (ADA) data from the phase III POSEIDON trial
|
Reinmuth, N.
|
|
|
32 |
S7 |
p. S1449
|
artikel
|
| 67 |
34P Dynamic changes in plasma PD-L1 in patients with gliomas: Prognostic value and association with IDH status
|
Cabezas-Camarero, S.
|
|
|
32 |
S7 |
p. S1387
|
artikel
|
| 68 |
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
|
Mazzaschi, G.
|
|
|
32 |
S7 |
p. S1380-S1381
|
artikel
|
| 69 |
124P Effective silencing of PD-1 gene in human peripheral blood T-lymphocytes by self-deliverable siRNA
|
Bogdanov, A.
|
|
|
32 |
S7 |
p. S1432
|
artikel
|
| 70 |
185P Effect of 17β-estradiol and prolactin in the cytotoxicity of NK cells on cervical cancer cells
|
Pereira-Suárez, A.L.
|
|
|
32 |
S7 |
p. S1462-S1463
|
artikel
|
| 71 |
104P Exploring the real-world impact of COVID-19 on first line (1L) treatment and management of EGFR-wild type (EGFR-WT) and ALK-wild type (ALK-WT) metastatic non-small cell lung cancer (mNSCLC) across Europe
|
Bailey, H.
|
|
|
32 |
S7 |
p. S1420
|
artikel
|
| 72 |
82P Exploring treatment patterns and outcomes of patients with advanced lung cancer (aLC) using artificial intelligence (AI)-extracted data
|
Cheung, W.Y.
|
|
|
32 |
S7 |
p. S1407
|
artikel
|
| 73 |
128P Ex-vivo co-blockade of CD-155/TIGIT and PD-1/PD-L1 using CCAT-1, H19 and MALAT-1 LncRNAs in hepatocellular carcinoma
|
Youness, R.A.
|
|
|
32 |
S7 |
p. S1433
|
artikel
|
| 74 |
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status
|
Cortellini, A.
|
|
|
32 |
S7 |
p. S1378
|
artikel
|
| 75 |
191P Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB)
|
Traweek, R.
|
|
|
32 |
S7 |
p. S1464
|
artikel
|
| 76 |
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
|
Di Giacomo, A.M.
|
|
|
32 |
S7 |
p. S1438
|
artikel
|
| 77 |
135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors
|
Patnaik, A.
|
|
|
32 |
S7 |
p. S1435-S1436
|
artikel
|
| 78 |
26P Genome-wide copy number variation of circulating cell-free DNA as a biomarker in head and neck cancer patients treated with immunotherapy
|
Zhu, Y.
|
|
|
32 |
S7 |
p. S1384
|
artikel
|
| 79 |
31P Genomic landscape and actionable targets as identified by whole genome sequencing and RNA sequencing in patients with advanced renal cell carcinoma
|
Joode, K.D.
|
|
|
32 |
S7 |
p. S1386
|
artikel
|
| 80 |
178P Glioblastoma multiforme cells down-regulate TNFα-mediated antitumor killer activity of dendritic cells
|
Tyrinova, T.
|
|
|
32 |
S7 |
p. S1460
|
artikel
|
| 81 |
113P Health outcomes and budget impact projection of the anti-PD-(L)1 class in cancer care in Portugal
|
Costa, L.
|
|
|
32 |
S7 |
p. S1424-S1425
|
artikel
|
| 82 |
163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study
|
Chan, A.T.C.
|
|
|
32 |
S7 |
p. S1452
|
artikel
|
| 83 |
187P Hematopoietic stem cell mobilization leads to the expansion of circulating myeloid-derived suppressor cells in multiple myeloma patients
|
Aristova, T.
|
|
|
32 |
S7 |
p. S1463
|
artikel
|
| 84 |
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab
|
Romano, F.J.
|
|
|
32 |
S7 |
p. S1379
|
artikel
|
| 85 |
9P HLA-I homozygosity as a predictive biomarker for developing immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy
|
Abed, A.
|
|
|
32 |
S7 |
p. S1378
|
artikel
|
| 86 |
20P Identifying novel biomarkers with deep proteomics profiling and survival analysis in NSCLC patients treated with anti-PD-1-blockade
|
Nguyen, E.
|
|
|
32 |
S7 |
p. S1382
|
artikel
|
| 87 |
130P IL-2-armed oncolytic vaccinia virus exerts potent antitumor effects in human pancreatic cancer
|
Wang, R.
|
|
|
32 |
S7 |
p. S1434
|
artikel
|
| 88 |
79P Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
|
Mazzarella, L.
|
|
|
32 |
S7 |
p. S1406
|
artikel
|
| 89 |
112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents
|
Muñoz, F. Longo
|
|
|
32 |
S7 |
p. S1424
|
artikel
|
| 90 |
152P Immunotherapy-based strategies displayed a promising efficacy in non-small cell lung cancer (NSCLC) patients with non-EGFR oncogenic genetic alterations
|
Zhang, Y.
|
|
|
32 |
S7 |
p. S1446
|
artikel
|
| 91 |
75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy
|
Huynh, L.
|
|
|
32 |
S7 |
p. S1404-S1405
|
artikel
|
| 92 |
174P Impact of cabozantinib on dendritic and natural killer cell immune responses in a murine syngeneic tumor model
|
Divoux, J.
|
|
|
32 |
S7 |
p. S1459
|
artikel
|
| 93 |
61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC
|
Patel, S.P.
|
|
|
32 |
S7 |
p. S1398-S1399
|
artikel
|
| 94 |
102P IMreal Cohort 2: First interim analysis of patient (pt) characteristics and safety data in pts with locally advanced or metastatic NSCLC (aNSCLC) receiving atezolizumab (atezo) under real-world conditions
|
Girard, N.
|
|
|
32 |
S7 |
p. S1418-S1419
|
artikel
|
| 95 |
147P Inductive anti-PD-1 and albumin paclitaxel/cisplatin on pathological response in patients with locally advanced oral squamous cell carcinoma: A single arm trial
|
Zhong, L-P.
|
|
|
32 |
S7 |
p. S1443
|
artikel
|
| 96 |
72P Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|
Diab, A.
|
|
|
32 |
S7 |
p. S1403
|
artikel
|
| 97 |
40P Interplay between mutational profile and TMB on overall survival: A post hoc analysis of 1,662 metastatic patients treated with immune checkpoint inhibitors
|
Xavier, C.B.
|
|
|
32 |
S7 |
p. S1389
|
artikel
|
| 98 |
149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
|
Munoz Couselo, E.
|
|
|
32 |
S7 |
p. S1444-S1445
|
artikel
|
| 99 |
127P Lactobacillus plantarum IMB19 exerts anti-tumor immunity by enhancing effector functions of tumor associated type 1 macrophage and CD8+ T-cells
|
Im, S-H.
|
|
|
32 |
S7 |
p. S1433
|
artikel
|
| 100 |
87P Landscape of immune-checkpoint inhibitors for metastatic colorectal cancer: A meta-analysis
|
Shek, D.
|
|
|
32 |
S7 |
p. S1410
|
artikel
|
| 101 |
95P Long-term outcomes in patients with BRAF-mutant advanced melanoma: A real-world study
|
Amin, A.
|
|
|
32 |
S7 |
p. S1415-S1416
|
artikel
|
| 102 |
125P LSD1 inhibition restores MHC class I expression and augments the anti-tumor response of immune checkpoint blockade in small cell lung cancer
|
Sen, T.
|
|
|
32 |
S7 |
p. S1432
|
artikel
|
| 103 |
76P Need for awareness about immune-related adverse events (iRAEs) among community physicians in India
|
Koyyala, V.P.B.
|
|
|
32 |
S7 |
p. S1405
|
artikel
|
| 104 |
145P Neoadjuvant chemotherapy combined with camrelizumab for locally advanced head and neck squamous cell carcinoma: A phase II trial
|
Yang, K.
|
|
|
32 |
S7 |
p. S1442-S1443
|
artikel
|
| 105 |
110P Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis
|
Lv, H.
|
|
|
32 |
S7 |
p. S1423
|
artikel
|
| 106 |
64P Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)
|
Yan, S.
|
|
|
32 |
S7 |
p. S1400
|
artikel
|
| 107 |
55P Neoantigen-reactive CD8 T-cells experience broadened and activated recognition profile following PD-L1 blockade and 1000-fold neoantigen-specific expansion using ImmPACT scaffolds
|
Holm, J. Sejerø
|
|
|
32 |
S7 |
p. S1395
|
artikel
|
| 108 |
101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting
|
Assie, J-B.
|
|
|
32 |
S7 |
p. S1418
|
artikel
|
| 109 |
143P Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data
|
Liu, J.
|
|
|
32 |
S7 |
p. S1442
|
artikel
|
| 110 |
126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies
|
Zorko, N.
|
|
|
32 |
S7 |
p. S1433
|
artikel
|
| 111 |
133P Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
|
Guillaudeux, T.
|
|
|
32 |
S7 |
p. S1435
|
artikel
|
| 112 |
59P Oncolytic adenovirus-based therapeutics to target or reprogram glioma-associated macrophages
|
de Sostoa, J.
|
|
|
32 |
S7 |
p. S1397
|
artikel
|
| 113 |
56P Optimization of manufacturing conditions CAR T-cells with 4-1BB costimulatory domain
|
Angelats, L.
|
|
|
32 |
S7 |
p. S1396
|
artikel
|
| 114 |
70P Outcomes in patients treated with taxane regimen after immune checkpoint inhibitors failure in advanced or metastatic non-small cell lung cancer
|
Guillemois, S.
|
|
|
32 |
S7 |
p. S1402-S1403
|
artikel
|
| 115 |
179P Paracrine crosstalk between LncRNA DILC and TNF-α release in tumor microenvironment of triple negative breast cancer
|
El Tayebi, H.M.
|
|
|
32 |
S7 |
p. S1460
|
artikel
|
| 116 |
94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
|
Fang, J.
|
|
|
32 |
S7 |
p. S1415
|
artikel
|
| 117 |
93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
|
Makharadze, T.
|
|
|
32 |
S7 |
p. S1414
|
artikel
|
| 118 |
35P PD-1+ and TIM-3+ T-cells differ in the expression of common γ-chain cytokine receptors after AHSCT in multiple myeloma patients
|
Batorov, E.
|
|
|
32 |
S7 |
p. S1387
|
artikel
|
| 119 |
62P PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A pooled analysis of three randomized trials
|
Chen, Y.
|
|
|
32 |
S7 |
p. S1399
|
artikel
|
| 120 |
92P PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
|
García Campelo, M.R.
|
|
|
32 |
S7 |
p. S1413-S1414
|
artikel
|
| 121 |
37P PD-L1 on the endothelium of micrangium inside tumor: A novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450)?
|
Ma, L.
|
|
|
32 |
S7 |
p. S1388
|
artikel
|
| 122 |
6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407
|
Cheng, Y.
|
|
|
32 |
S7 |
p. S1376-S1377
|
artikel
|
| 123 |
160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
|
Ponce Aix, S.
|
|
|
32 |
S7 |
p. S1450
|
artikel
|
| 124 |
159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma
|
De Jaeghere, E.A.
|
|
|
32 |
S7 |
p. S1449-S1450
|
artikel
|
| 125 |
141P Phase Ib study of the TLR7 agonist TQ-A3334 monotherapy or combined with anlotinib or PD-L1 inhibitor in treatment of advanced metastatic non-small cell lung cancer
|
Song, Y.
|
|
|
32 |
S7 |
p. S1440
|
artikel
|
| 126 |
91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein
|
Davar, D.
|
|
|
32 |
S7 |
p. S1411-S1413
|
artikel
|
| 127 |
136P Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
|
Prenen, H.
|
|
|
32 |
S7 |
p. S1436
|
artikel
|
| 128 |
137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
|
Richardson, G.
|
|
|
32 |
S7 |
p. S1436-S1437
|
artikel
|
| 129 |
172P Phenotypic and functional heterogeneity of tissue resident memory T-cells in colorectal cancer liver metastasis
|
Abdeljaoued, S.
|
|
|
32 |
S7 |
p. S1458
|
artikel
|
| 130 |
180P Photodynamic priming of pancreatic cancer: Enabling immunotherapy
|
De Silva, P.
|
|
|
32 |
S7 |
p. S1460-S1461
|
artikel
|
| 131 |
108P PICTuRE: Real-world treatment pathways in stage III non-small cell lung cancer in Portugal
|
Teixeira, M.E.
|
|
|
32 |
S7 |
p. S1421
|
artikel
|
| 132 |
27P Plasma-derived exosomes as biomarkers for therapy monitoring in head and neck cancer patients treated with surgery and (chemo)radiotherapy
|
Hofmann, L.
|
|
|
32 |
S7 |
p. S1385
|
artikel
|
| 133 |
181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations
|
Makarem, M.
|
|
|
32 |
S7 |
p. S1461
|
artikel
|
| 134 |
162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors
|
Even, C.
|
|
|
32 |
S7 |
p. S1451-S1452
|
artikel
|
| 135 |
84P Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)
|
Faivre-Finn, C.
|
|
|
32 |
S7 |
p. S1408-S1409
|
artikel
|
| 136 |
41P Predicting response to checkpoint inhibitors using complex molecular characteristics and immunoprofiling in solid tumours
|
Borilova, S.
|
|
|
32 |
S7 |
p. S1389
|
artikel
|
| 137 |
74P Predicting the risk of immunotherapy-induced versus other-cause pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors
|
Tohidinezhad, F.
|
|
|
32 |
S7 |
p. S1404
|
artikel
|
| 138 |
21P Predictive immunological markers of anti-PD-1/PD-L1 therapy efficacy in non-small cell lung cancer
|
Musaelyan, A.A.
|
|
|
32 |
S7 |
p. S1382
|
artikel
|
| 139 |
164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
|
Sharma, M.R.
|
|
|
32 |
S7 |
p. S1453-S1454
|
artikel
|
| 140 |
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
|
Felip, E.
|
|
|
32 |
S7 |
p. S1438-S1440
|
artikel
|
| 141 |
138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
|
Bishnoi, S.
|
|
|
32 |
S7 |
p. S1437-S1438
|
artikel
|
| 142 |
8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab
|
Elshiaty, M.
|
|
|
32 |
S7 |
p. S1377-S1378
|
artikel
|
| 143 |
189P Prognostic significance of lymphocyte activation gene-3 (LAG3 gene) in uveal melanoma patients
|
Singh, L.
|
|
|
32 |
S7 |
p. S1463-S1464
|
artikel
|
| 144 |
173P Pseudotime dynamics in pancreatic ductal adenocarcinoma reveal different mechanisms of hindrance in immunity through bifurcation of regulatory and cytotoxic T-cell differentiation
|
Jainarayanan, A.K.
|
|
|
32 |
S7 |
p. S1458-S1459
|
artikel
|
| 145 |
146P Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the CISPD-4 study)
|
Chen, Y.
|
|
|
32 |
S7 |
p. S1443
|
artikel
|
| 146 |
106P Real-world outcomes in extensive-stage small cell lung cancer with PD-L1 inhibitors in China
|
Meng, X.
|
|
|
32 |
S7 |
p. S1420-S1421
|
artikel
|
| 147 |
111P Real-world treatment modification of first-line axitinib + pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
|
Zakharia, Y.
|
|
|
32 |
S7 |
p. S1423-S1424
|
artikel
|
| 148 |
103P Real-world treatment patterns before and after receiving PD-L1 test results in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
|
Antonia, S.J.
|
|
|
32 |
S7 |
p. S1419-S1420
|
artikel
|
| 149 |
33P Relation of T-cell infiltration and PD-L1 expression with IDH and MGMT status in gliomas: Prognostic value and role for immunotherapy development
|
Cabezas-Camarero, S.
|
|
|
32 |
S7 |
p. S1387
|
artikel
|
| 150 |
154P Results of an open-label, phase Ia/Ib study of olaratumab plus pembrolizumab in patients with unresectable, locally advanced or metastatic soft tissue sarcoma
|
Schöffski, P.
|
|
|
32 |
S7 |
p. S1447
|
artikel
|
| 151 |
71P Safety and efficacy of salvage radiotherapy after progression to checkpoint inhibitors in recurrent and/or metastatic head and neck cancer
|
Cabezas-Camarero, S.
|
|
|
32 |
S7 |
p. S1403
|
artikel
|
| 152 |
156P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib study
|
Cui, C.
|
|
|
32 |
S7 |
p. S1448
|
artikel
|
| 153 |
153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
|
Goh, J.C.
|
|
|
32 |
S7 |
p. S1446-S1447
|
artikel
|
| 154 |
11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature
|
Naigeon, M.
|
|
|
32 |
S7 |
p. S1379
|
artikel
|
| 155 |
15P Serum immune checkpoint biomarkers as predictors of response to anti-PD-1/PD-L1 treatment in non-small cell lung cancer (NSCLC) patients
|
Raza, A.
|
|
|
32 |
S7 |
p. S1380
|
artikel
|
| 156 |
90P Sex difference in side effects of immunotherapy in a population of patients with non-small cell lung cancer
|
Valota, M.
|
|
|
32 |
S7 |
p. S1411
|
artikel
|
| 157 |
63P Shifting treatment landscape and overall survival (OS) by PD-L1 expression level among patients (pts) with advanced non-small cell lung cancer (aNSCLC)
|
Dietz, H.
|
|
|
32 |
S7 |
p. S1399-S1400
|
artikel
|
| 158 |
67P Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase II trial
|
Luo, Z.
|
|
|
32 |
S7 |
p. S1401
|
artikel
|
| 159 |
100P SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT)
|
Mooradian, M.J.
|
|
|
32 |
S7 |
p. S1417-S1418
|
artikel
|
| 160 |
16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer
|
Kulasinghe, A.
|
|
|
32 |
S7 |
p. S1380
|
artikel
|
| 161 |
150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer
|
Zhou, C.
|
|
|
32 |
S7 |
p. S1445
|
artikel
|
| 162 |
155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study
|
Lu, M.
|
|
|
32 |
S7 |
p. S1448
|
artikel
|
| 163 |
157P Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of first-line systemic chemotherapy
|
Cheng, Y.
|
|
|
32 |
S7 |
p. S1448-S1449
|
artikel
|
| 164 |
89P Survival and immunotoxicity profiles in younger versus elderly patients with metastatic renal cell cancer undergoing immunotherapy
|
Zhang, J.
|
|
|
32 |
S7 |
p. S1410-S1411
|
artikel
|
| 165 |
38P The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
|
Guven, D.C.
|
|
|
32 |
S7 |
p. S1388
|
artikel
|
| 166 |
85P The association between diabetes and survival in patients treated with immunotherapy
|
Guven, D.C.
|
|
|
32 |
S7 |
p. S1409
|
artikel
|
| 167 |
77P The Belgian Multidisciplinary Immunotoxicity Board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO)
|
Verhaert, M.
|
|
|
32 |
S7 |
p. S1405
|
artikel
|
| 168 |
107P The evolving diagnostic and treatment landscape in metastatic non-small cell lung cancer (mNSCLC) across Europe: A real world evidence survey
|
Bailey, H.
|
|
|
32 |
S7 |
p. S1421
|
artikel
|
| 169 |
52P The inducible Medigene T-cell receptor (iM-TCR) controls cytotoxicity of tumor-specific TCR-modified T-cells with improved avidity through control of TCR surface expression
|
Acs, A.
|
|
|
32 |
S7 |
p. S1394
|
artikel
|
| 170 |
29P The multi-switching activity of circulatory neutrophils in patients with early breast cancer
|
Ramessur, A.
|
|
|
32 |
S7 |
p. S1385
|
artikel
|
| 171 |
19P Therapeutic targets in non-small cell lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and its associated molecular landscape
|
Adam, J.
|
|
|
32 |
S7 |
p. S1381
|
artikel
|
| 172 |
188P TIM-3 expression and markers of immune escape on leukemia cells
|
Kuzelova, K.
|
|
|
32 |
S7 |
p. S1463
|
artikel
|
| 173 |
144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study
|
Yan, X.
|
|
|
32 |
S7 |
p. S1442
|
artikel
|
| 174 |
177P TP53 and PRBM1 mutations predict “hot” tumor microenvironment in intrahepatic cholangiocarcinoima
|
Lozzi Da Costa, I.
|
|
|
32 |
S7 |
p. S1460
|
artikel
|
| 175 |
190P Transcriptomic molecular subtypes of esophageal squamous cell carcinoma predicted the prognosis and efficacy of neo-adjuvant immunotherapy
|
Liu, J.
|
|
|
32 |
S7 |
p. S1464
|
artikel
|
| 176 |
131P Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects
|
Milleri, S.
|
|
|
32 |
S7 |
p. S1434
|
artikel
|
| 177 |
51P Translational analyses of the DeCidE phase II clinical study in advanced ovarian cancer patients reveal a substantial role for B-cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment
|
Dorigo, O.
|
|
|
32 |
S7 |
p. S1394
|
artikel
|
| 178 |
109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France
|
Griesinger, F.
|
|
|
32 |
S7 |
p. S1422-S1423
|
artikel
|
| 179 |
97P Trends and disparities in real-world (RW) biomarker testing (BT) and overall survival (OS) among US patients (pts) with advanced non-small cell lung cancer (aNSCLC), 2015–2020
|
Antonia, S.J.
|
|
|
32 |
S7 |
p. S1416-S1417
|
artikel
|
| 180 |
132P Tumor-responsive nanoparticles exhibit selective immunomodulatory effects: A Trojan horse strategy
|
Sebak, A.
|
|
|
32 |
S7 |
p. S1434
|
artikel
|
| 181 |
176P Type of TP53 alteration may correlate with the extent of lymphocytic infiltration in high-grade serous ovarian carcinomas
|
Sokolenko, A.
|
|
|
32 |
S7 |
p. S1459
|
artikel
|
| 182 |
142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
|
Price, T.J.
|
|
|
32 |
S7 |
p. S1440-S1442
|
artikel
|
| 183 |
24P Using real-world evidence data and machine learning to identify molecular biomarkers for patient response to immune checkpoint inhibitors in metastatic melanoma
|
Siozopoulou, V.
|
|
|
32 |
S7 |
p. S1383
|
artikel
|
| 184 |
96P US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
|
Bittoni, M.A.
|
|
|
32 |
S7 |
p. S1416
|
artikel
|
| 185 |
105P US real-world treatment patterns and outcomes of metastatic nonsquamous non-small cell lung cancer (mNSQ NSCLC) patients (pts) after progression on standard of care (SOC)
|
Bittoni, M.A.
|
|
|
32 |
S7 |
p. S1420
|
artikel
|
| 186 |
58P Validation of the Achilles VELOS process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T-cells
|
Samuel, E.R.
|
|
|
32 |
S7 |
p. S1396-S1397
|
artikel
|
| 187 |
Table of Contents
|
|
|
|
32 |
S7 |
p. vii
|
artikel
|
| 188 |
167TiP AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
|
Xing, L.
|
|
|
32 |
S7 |
p. S1455
|
artikel
|
| 189 |
165TiP A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies
|
Garralda, E.
|
|
|
32 |
S7 |
p. S1454
|
artikel
|
| 190 |
118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress
|
Yang, J.
|
|
|
32 |
S7 |
p. S1426-S1427
|
artikel
|
| 191 |
117TiP A phase II study of toripalimab combined with paclitaxel/carboplatin for the first-line treatment of advanced thymic carcinoma
|
Hu, X.
|
|
|
32 |
S7 |
p. S1426
|
artikel
|
| 192 |
170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors
|
Jeger, S.
|
|
|
32 |
S7 |
p. S1456-S1457
|
artikel
|
| 193 |
119TiP Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC: The DIRECT-trial
|
Dickhoff, C.
|
|
|
32 |
S7 |
p. S1427
|
artikel
|
| 194 |
168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)
|
Halmos, B.
|
|
|
32 |
S7 |
p. S1456
|
artikel
|
| 195 |
116TiP KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti–PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)
|
Lai, W.C.V.
|
|
|
32 |
S7 |
p. S1425-S1426
|
artikel
|
| 196 |
114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)
|
Peled, N.
|
|
|
32 |
S7 |
p. S1425
|
artikel
|
| 197 |
166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phase III clinical study (Keystone-002)
|
Jiang, H.
|
|
|
32 |
S7 |
p. S1454-S1455
|
artikel
|
| 198 |
115TiP Stereotactic body radiotherapy (SBRT) plus anlotinib with or without toripalimab in driver mutation-negative non-small cell lung cancer (NSCLC) patients with untreated brain oligometastatic metastases: A prospective, single-center, phase Ib study
|
Han, G.
|
|
|
32 |
S7 |
p. S1425
|
artikel
|
| 199 |
169TiP Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma
|
Diab, A.
|
|
|
32 |
S7 |
p. S1456
|
artikel
|
| 200 |
Title Page
|
|
|
|
32 |
S7 |
p. iv
|
artikel
|
Tijdschrift beschrijving